Eagle Pharmaceuticals (EGRX) Stock Price, News & Analysis

+0.22 (+4.84%)
(As of 04/23/2024 ET)
Today's Range
50-Day Range
52-Week Range
88,216 shs
Average Volume
219,450 shs
Market Capitalization
$61.96 million
P/E Ratio
Dividend Yield
Price Target

Eagle Pharmaceuticals MarketRank™ Stock Analysis

Analyst Rating
1.00 Rating Score
256.4% Upside
$17.00 Price Target
Short Interest
10.59% of Float Sold Short
Dividend Strength
Upright™ Environmental Score
News Sentiment
Insider Trading
Proj. Earnings Growth

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

3.78 out of 5 stars

Medical Sector

215th out of 909 stocks

Pharmaceutical Preparations Industry

88th out of 425 stocks

EGRX stock logo

About Eagle Pharmaceuticals Stock (NASDAQ:EGRX)

Eagle Pharmaceuticals, Inc., a pharmaceutical company, focuses on developing and commercializing product candidates to treat diseases of the central nervous system or metabolic critical care, and oncology in the United States. The company offers Ryanodex for malignant hyperthermia; and Belrapzo and Bendeka for chronic lymphocytic leukemia and indolent B-cell non-Hodgkin's lymphoma. Its product candidates also include EP-4104, a dantrolene sodium to treat organophosphate exposure; PEMFEXY, a ready-to-use/dilute liquid form of pemetrexed for non-small cell lung cancer and mesothelioma; EA-114 (fulvestrant) for HR+/HER- breast cancer; and Vasopressin injection, which is indicated to enhance blood pressure in adults with vasodilatory shock. The company has license and collaboration agreements with Combioxin, SA for the development and commercialization rights to CAL02, an antitoxin agent for the treatment of severe pneumonia in combination with traditional antibacterial drugs; and AOP Orphan Pharmaceuticals GmbH for the commercial rights of Landiolol, a novel therapeutic product candidate for the short-term reduction of ventricular rate in patients with supraventricular tachycardia, including atrial fibrillation and atrial flutter. It has a strategic collaboration with Tyme Technologies, Inc. for the development of SM-88 to treat breast cancer (HR+/HER2-) and high-risk metastatic sarcomas. Eagle Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Woodcliff Lake, New Jersey.

EGRX Stock Price History

EGRX Stock News Headlines

One trade. One ticker. One week.
Do you want to target weekly income of up to $2k or more… Starting with just $500... With just one trade per week?
Stocks Mixed as Bond Yields Climb
One trade. One ticker. One week.
Do you want to target weekly income of up to $2k or more… Starting with just $500... With just one trade per week?
See More Headlines
Receive EGRX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Eagle Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
Next Earnings (Estimated)
Fiscal Year End

Industry, Sector and Symbol

Pharmaceutical preparations
Current Symbol
Year Founded

Price Target and Rating

Average Stock Price Target
High Stock Price Target
Low Stock Price Target
Potential Upside/Downside
Consensus Rating
Rating Score (0-4)
Research Coverage
1 Analysts


Pretax Margin


Sales & Book Value

Annual Sales
$316.61 million
Cash Flow
$3.91 per share
Book Value
$17.94 per share


Free Float
Market Cap
$61.96 million

Social Links

12 Stocks Corporate Insiders are Abandoning Cover

If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know?

Get This Free Report

Key Executives

  • Mr. Michael Graves (Age 61)
    Interim Principal Executive Officer & Executive Chairman of the Board
    Comp: $160k
  • Mr. Steven B. Ratoff (Age 81)
    Interim CFO, Principal Accounting Officer & Director
    Comp: $100k
  • Mr. Daniel O'Connor (Age 44)
    Executive VP, Chief Strategy Officer & Head of Corporate Development
  • Dr. Valentin R. Curt M.D.
    Senior Vice President of Clinical Drug Development
  • Dr. Gaozhong Zhu Ph.D.
    Senior Vice President of Pharmaceutical Development
  • Ms. Debra M. Hussain
    Senior VP & Head of Commercial
  • Mr. Reed McClung
    Executive Vice President of Oncology Business Development

EGRX Stock Analysis - Frequently Asked Questions

Should I buy or sell Eagle Pharmaceuticals stock right now?

1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Eagle Pharmaceuticals in the last twelve months. There are currently 1 sell rating for the stock. The consensus among Wall Street research analysts is that investors should "sell" EGRX shares.
View EGRX analyst ratings
or view top-rated stocks.

What is Eagle Pharmaceuticals' stock price target for 2024?

1 Wall Street analysts have issued 1 year price targets for Eagle Pharmaceuticals' stock. Their EGRX share price targets range from $17.00 to $17.00. On average, they predict the company's stock price to reach $17.00 in the next twelve months. This suggests a possible upside of 256.4% from the stock's current price.
View analysts price targets for EGRX
or view top-rated stocks among Wall Street analysts.

How have EGRX shares performed in 2024?

Eagle Pharmaceuticals' stock was trading at $5.23 at the beginning of 2024. Since then, EGRX stock has decreased by 8.8% and is now trading at $4.77.
View the best growth stocks for 2024 here

When is Eagle Pharmaceuticals' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, May 14th 2024.
View our EGRX earnings forecast

How were Eagle Pharmaceuticals' earnings last quarter?

Eagle Pharmaceuticals, Inc. (NASDAQ:EGRX) released its quarterly earnings results on Tuesday, November, 9th. The specialty pharmaceutical company reported $0.56 earnings per share for the quarter, beating analysts' consensus estimates of ($0.44) by $1.00. The specialty pharmaceutical company had revenue of $39.85 million for the quarter, compared to analysts' expectations of $46.70 million. During the same period last year, the company earned $0.51 earnings per share.

What other stocks do shareholders of Eagle Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Eagle Pharmaceuticals investors own include Gilead Sciences (GILD), Exelixis (EXEL), Teekay Tankers (TNK), AbbVie (ABBV), Intercept Pharmaceuticals (ICPT), Radius Recycling (RDUS), bluebird bio (BLUE), Clovis Oncology (CLVS), GW Pharmaceuticals (GWPH) and Incyte (INCY).

Who are Eagle Pharmaceuticals' major shareholders?

Eagle Pharmaceuticals' stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Los Angeles Capital Management LLC (1.48%) and DGS Capital Management LLC (0.48%). Insiders that own company stock include Richard A Edlin and Scott Tarriff.
View institutional ownership trends

How do I buy shares of Eagle Pharmaceuticals?

Shares of EGRX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:EGRX) was last updated on 4/23/2024 by Staff

From Our Partners